发布求助
文献互助 智能选刊 最新文献

Lung Cancer Management最新文献

筛选
英文 中文
Lung cancer management challenges amidst COVID-19 pandemic: hope lives here. COVID-19大流行给肺癌管理带来的挑战：希望就在这里。
IF 0.9
Lung Cancer Management Pub Date : 2020-05-01 DOI: 10.2217/lmt-2020-0012
Abhishek Shankar, Deepak Saini, Ruchir Bhandari, Sachidanand Jee Bharati, Sunil Kumar, Geetika Yadav, Tarun Durga, Nalin Goyal
{"title":"Lung cancer management challenges amidst COVID-19 pandemic: hope lives here.","authors":"Abhishek Shankar, Deepak Saini, Ruchir Bhandari, Sachidanand Jee Bharati, Sunil Kumar, Geetika Yadav, Tarun Durga, Nalin Goyal","doi":"10.2217/lmt-2020-0012","DOIUrl":"10.2217/lmt-2020-0012","url":null,"abstract":"","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 3","pages":"LMT33"},"PeriodicalIF":0.9,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1a/97/lmt-09-33.PMC7202360.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38249095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma. 通过生物信息学分析鉴定9个预测吸烟诱导肺腺癌不良预后的关键基因。
IF 2.8
Lung Cancer Management Pub Date : 2020-04-27 DOI: 10.2217/lmt-2020-0009
Chuanli Ren, Weixiu Sun, Xu Lian, Chongxu Han
{"title":"Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma.","authors":"Chuanli Ren,&nbsp;Weixiu Sun,&nbsp;Xu Lian,&nbsp;Chongxu Han","doi":"10.2217/lmt-2020-0009","DOIUrl":"https://doi.org/10.2217/lmt-2020-0009","url":null,"abstract":"<p><strong>Aim: </strong>To screen and identify key genes related to the development of smoking-induced lung adenocarcinoma (LUAD).</p><p><strong>Materials & methods: </strong>We obtained data from the GEO chip dataset GSE31210. The differentially expressed genes were screened by GEO2R. The protein interaction network of differentially expressed genes was constructed by STRING and Cytoscape. Finally, core genes were screened. The overall survival time of patients with the core genes was analyzed by Kaplan-Meier method. Gene ontology and Kyoto encyclopedia of genes and genomes bioaccumulation was calculated by DAVID.</p><p><strong>Results: </strong>Functional enrichment analysis indicated that nine key genes were actively involved in the biological process of smoking-related LUAD.</p><p><strong>Conclusion: </strong>23 core genes and nine key genes among them were correlated with adverse prognosis of LUAD induced by smoking.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT30"},"PeriodicalIF":2.8,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. 肺癌的预处理营养状况和对检查点抑制剂的反应。
IF 2.8
Lung Cancer Management Pub Date : 2020-04-24 DOI: 10.2217/lmt-2020-0008
Chung-Shien Lee, Craig E Devoe, Xinhua Zhu, Joanna Stein Fishbein, Nagashree Seetharamu
{"title":"Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.","authors":"Chung-Shien Lee,&nbsp;Craig E Devoe,&nbsp;Xinhua Zhu,&nbsp;Joanna Stein Fishbein,&nbsp;Nagashree Seetharamu","doi":"10.2217/lmt-2020-0008","DOIUrl":"https://doi.org/10.2217/lmt-2020-0008","url":null,"abstract":"<p><strong>Background: </strong>Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data suggests that nutritional status may play a role in antitumor immunity.</p><p><strong>Materials & methods: </strong>This retrospective study of 106 non-small-cell lung cancer patients who started checkpoint inhibitors between 2014 and 2017 at our institution assessed relationship of nutritional parameters to overall survival (OS) and progression-free survival.</p><p><strong>Results: </strong>Mean age was 68.7 ± 9.2 years and 59.4% patients were male. On multivariate analysis for OS, hypoalbuminemia and significant weight loss were prognostic at p-values of 0.0005 and 0.0052, respectively. We noted a parabolic association between age and OS (p = 0.026, 0.0025).</p><p><strong>Conclusion: </strong>In our study, some malnutrition parameters were associated with decreased OS. U-shape relationship between age and OS noted here warrants further evaluation.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT31"},"PeriodicalIF":2.8,"publicationDate":"2020-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung. 立体定向消融体放疗对早期肺大细胞神经内分泌癌的分级放疗比较。
IF 2.8
Lung Cancer Management Pub Date : 2020-04-21 DOI: 10.2217/lmt-2020-0004
Rodney E Wegner, Stephen Abel, Athanasios Colonias
{"title":"Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung.","authors":"Rodney E Wegner,&nbsp;Stephen Abel,&nbsp;Athanasios Colonias","doi":"10.2217/lmt-2020-0004","DOIUrl":"https://doi.org/10.2217/lmt-2020-0004","url":null,"abstract":"<p><strong>Aim: </strong>Some patients with early stage large cell neuroendocrine carcinoma (LCNEC) of the lung are not surgical candidates and will be managed with radiotherapy. We used the national cancer database to identify predictors of stereotactic radiotherapy and compare outcomes.</p><p><strong>Materials & methods: </strong>We queried national cancer database for T1-2N0 LCNEC treated with radiation. Logistic regression and Cox regression identified predictors of stereotactic ablative body radiotherapy (SABR) and survival, respectively.</p><p><strong>Results: </strong>We identified 754 patients, with 238 (32%) treated with SABR. Predictors of SABR were distance to facility, no chemotherapy, academic center, T1 and recent year. After propensity matching, median survival was 34.7 months compared with 23.7 months in favor of SABR (p = 0.02).</p><p><strong>Conclusion: </strong>SABR for LCNEC has increased over time and was associated with improved survival.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 3","pages":"LMT32"},"PeriodicalIF":2.8,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38245940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Welcome to Volume 9 of Lung Cancer Management. 欢迎来到《肺癌管理》第九卷。
IF 2.8
Lung Cancer Management Pub Date : 2020-03-24 DOI: 10.2217/lmt-2020-0007
Katherine Gordon
{"title":"Welcome to Volume 9 of <i>Lung Cancer Management</i>.","authors":"Katherine Gordon","doi":"10.2217/lmt-2020-0007","DOIUrl":"https://doi.org/10.2217/lmt-2020-0007","url":null,"abstract":"","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT27"},"PeriodicalIF":2.8,"publicationDate":"2020-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. EGFR突变阳性NSCLC从第一代或第二代EGFR- tki切换到奥西替尼。
IF 2.8
Lung Cancer Management Pub Date : 2020-03-19 DOI: 10.2217/lmt-2020-0005
Fumio Imamura, Takako Inoue, Kei Kunimasa, Aki Kubota, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Madoka Kimura, Kika Kuno, Hayato Kawachi, Toru Kumagai
{"title":"Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLC.","authors":"Fumio Imamura,&nbsp;Takako Inoue,&nbsp;Kei Kunimasa,&nbsp;Aki Kubota,&nbsp;Hanako Kuhara,&nbsp;Motohiro Tamiya,&nbsp;Kazumi Nishino,&nbsp;Madoka Kimura,&nbsp;Kika Kuno,&nbsp;Hayato Kawachi,&nbsp;Toru Kumagai","doi":"10.2217/lmt-2020-0005","DOIUrl":"https://doi.org/10.2217/lmt-2020-0005","url":null,"abstract":"<p><strong>Aim: </strong>We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for <i>EGFR</i> mutation-positive NSCLC.</p><p><strong>Materials & methods: </strong>Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for <i>T790M</i>-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.</p><p><strong>Results: </strong>Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.</p><p><strong>Conclusion: </strong>Switch use of osimertinib seemed to produce improved efficacy for patients with activating <i>EGFR</i> mutations, because of the lack of patient selection via <i>T790M</i>.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT29"},"PeriodicalIF":2.8,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. 晚期ALK+ NSCLC患者脑转移治疗的成本分析:阿勒替尼与克唑替尼
IF 2.8
Lung Cancer Management Pub Date : 2020-03-04 DOI: 10.2217/lmt-2019-0011
Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín, Itziar Oyagüez
{"title":"Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.","authors":"Dolores Isla,&nbsp;Bartomeu Massuti,&nbsp;Martín Lázaro,&nbsp;Lucía Ruiz de Alda,&nbsp;Rocio Gordo,&nbsp;Nuria Ortega-Joaquín,&nbsp;Itziar Oyagüez","doi":"10.2217/lmt-2019-0011","DOIUrl":"https://doi.org/10.2217/lmt-2019-0011","url":null,"abstract":"<p><strong>Aim: </strong>To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib.</p><p><strong>Methods: </strong>Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption provided by local oncologists, including medical visits, hospitalizations, diagnostic/laboratory tests, imaging techniques and surgical procedures. The comparison of costs/year with alectinib and crizotinib, considered the cumulative 12-month incidence of BM in ALEX trial (9.4 and 41.4%, respectively).</p><p><strong>Results: </strong>Management cost was €6173.42/patient-year without BM and €21,637.50/patient-year with BM. With alectinib, average cost/patient was lower than crizotinib (€4948.51/patient-year).</p><p><strong>Conclusion: </strong>Prevention of BM with alectinib may result in reductions of cost/year in the management of advanced ALK+ NSCLC.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT28"},"PeriodicalIF":2.8,"publicationDate":"2020-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis. T1-3N0 NSCLC脑转移风险:基于人群的分析
IF 2.8
Lung Cancer Management Pub Date : 2020-02-25 DOI: 10.2217/lmt-2019-0010
Michael T Milano, James E Bates, Justin Budnik, Haoming Qiu, Sara Hardy, Michael A Cummings, Megan A Baumgart, Ronald J Maggiore, Deborah A Mulford, Kenneth Y Usuki
{"title":"Risk of brain metastases in T1-3N0 NSCLC: a population-based analysis.","authors":"Michael T Milano,&nbsp;James E Bates,&nbsp;Justin Budnik,&nbsp;Haoming Qiu,&nbsp;Sara Hardy,&nbsp;Michael A Cummings,&nbsp;Megan A Baumgart,&nbsp;Ronald J Maggiore,&nbsp;Deborah A Mulford,&nbsp;Kenneth Y Usuki","doi":"10.2217/lmt-2019-0010","DOIUrl":"https://doi.org/10.2217/lmt-2019-0010","url":null,"abstract":"<p><strong>Aim: </strong>Several consensus guidelines recommend against routine brain imaging at diagnosis of T1-3N0 non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>From the Surveillance, Epidemiology and End Results registry, patients with pathologically confirmed T1-3N0 NSCLC were identified. Risks of brain metastases at time of initial diagnosis were analyzed.</p><p><strong>Results: </strong>Patients selected to not undergo primary NSCLC resection had approximately tenfold greater incidence of brain metastases versus those who did. Younger age, adenocarcinoma histology, higher tumor stage and higher histologic grade were all significantly (p < 0.0001) associated with greater likelihood of presenting with brain metastases.</p><p><strong>Conclusion: </strong>Given the morbidity and mortality of brain metastases, routine brain screening after NSCLC diagnosis (particularly adenocarcinoma) may be justifiable, though more refined cost-benefit analyses are warranted.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT25"},"PeriodicalIF":2.8,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. 晚期非小细胞肺癌患者BMI与免疫检查点抑制剂应答的相关性研究
IF 2.8
Lung Cancer Management Pub Date : 2020-02-25 DOI: 10.2217/lmt-2019-0016
Alain Gelibter, Mario Occhipinti, Simona Pisegna, Alessio Cortellini, Enrico Cortesi, Paolo Marchetti
{"title":"Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer.","authors":"Alain Gelibter,&nbsp;Mario Occhipinti,&nbsp;Simona Pisegna,&nbsp;Alessio Cortellini,&nbsp;Enrico Cortesi,&nbsp;Paolo Marchetti","doi":"10.2217/lmt-2019-0016","DOIUrl":"https://doi.org/10.2217/lmt-2019-0016","url":null,"abstract":"Alain Gelibter*,1, Mario Occhipinti1 , Simona Pisegna1, Alessio Cortellini2,3, Enrico Cortesi1 & Paolo Marchetti1,4 1Medical Oncology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy 2Medical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy 3Department of Biotechnological & Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 4U.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant’Andrea, Rome, Italy *Author for correspondence: alain.gelibter@uniroma1.it","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT26"},"PeriodicalIF":2.8,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer. 早期肺癌术后液体活检分子残留检测优化
IF 2.8
Lung Cancer Management Pub Date : 2020-02-21 DOI: 10.2217/lmt-2019-0017
Anna L McGuire, Curtis B Hughesman, Melissa K McConechy, Barb Melosky, Stephen Lam, Renelle Myers, John Yee, Ernest Tang, Stephen Yip
{"title":"Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer.","authors":"Anna L McGuire,&nbsp;Curtis B Hughesman,&nbsp;Melissa K McConechy,&nbsp;Barb Melosky,&nbsp;Stephen Lam,&nbsp;Renelle Myers,&nbsp;John Yee,&nbsp;Ernest Tang,&nbsp;Stephen Yip","doi":"10.2217/lmt-2019-0017","DOIUrl":"https://doi.org/10.2217/lmt-2019-0017","url":null,"abstract":"Anna L McGuire*,1, Curtis B Hughesman2, Melissa K McConechy3, Barb Melosky4,5, Stephen Lam4,6, Renelle Myers4,6, John Yee1, Ernest Tang1 & Stephen Yip2,7 1Department of Surgery, Division of Thoracic Surgery, Vancouver General Hospital, University of British Columbia, Vancouver V5Z1M9, BC, Canada 2Department of Pathology and Laboratory Medicine, BC Cancer, Cancer Genetics & Genomics Laboratory, Vancouver, BC, Canada 3Contextual Genomics Inc., Vancouver, BC, Canada 4Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Vancouver, BC, Canada 5Medical Oncology, University of British Columbia, Vancouver, BC, Canada 6Department of Medicine, Divisions of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada 7Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada *Author for correspondence: anna.mcguire@vch.ca","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT24"},"PeriodicalIF":2.8,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书